Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling

Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R)

(2020) Alexandra Fletcher-Jones et al.   Frontiers in Molecular Neuroscience

The endocannabinoid system is affected by cholesterol dyshomeostasis: Insights from a murine model of Niemann Pick type C disease

(2019) Sergio Oddi et al.   NEUROBIOLOGY OF DISEASE

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

(2018) Maria S. Aymerich et al.   BIOCHEMICAL PHARMACOLOGY

Lipid-metabolizing serine hydrolases in the mammalian central nervous system: endocannabinoids and beyond

(2018) Myungsun Shin et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Impaired anandamide/palmitoylethanolamide signaling in hippocampal glutamatergic neurons alters synaptic plasticity, learning, and emotional responses

(2018) Tina Zimmermann et al.   NEUROPSYCHOPHARMACOLOGY

Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency

(2017) Margaret M. McGovern et al.   GENETICS IN MEDICINE

Types A and B Niemann-Pick disease

(2017) Edward H. Schuchman et al.   MOLECULAR GENETICS AND METABOLISM

Crystal structures of agonist-bound human cannabinoid receptor CB1

(2017) Tian Hua et al.   NATURE

Sphingomyelin-induced inhibition of the plasma membrane calcium ATPase causes neurodegeneration in type A Niemann–Pick disease

(2016) A Pérez-Cañamás et al.   MOLECULAR PSYCHIATRY

Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease

(2016) Yolanda Gómez-Gálvez et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—A practical view

(2015) Christopher J. Fowler   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Nonclinical safety assessment of recombinant human acid sphingomyelinase (rhASM) for the treatment of acid sphingomyelinase deficiency: The utility of animal models of disease in the toxicological evaluation of potential therapeutics

(2015) James M. Murray et al.   MOLECULAR GENETICS AND METABOLISM

Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency

(2015) Melissa P. Wasserstein et al.   MOLECULAR GENETICS AND METABOLISM

Endocannabinoid Signaling in Autism

(2015) Bhismadev Chakrabarti et al.   Neurotherapeutics

High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A

(2014) E Gabandé-Rodríguez et al.   CELL DEATH AND DIFFERENTIATION

Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model

(2014) Ana I Arroyo et al.   EMBO Molecular Medicine

Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies

(2014) Mauro Maccarrone et al.   NATURE REVIEWS NEUROSCIENCE

A restricted population of CB1 cannabinoid receptors with neuroprotective activity

(2014) A. Chiarlone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the endocannabinoid system in the treatment of fragile X syndrome

(2013) Arnau Busquets-Garcia et al.   NATURE MEDICINE

Multiple Functions of Endocannabinoid Signaling in the Brain

(2012) István Katona et al.   Annual Review of Neuroscience

The Endocannabinoid System and the Brain

(2012) Raphael Mechoulam et al.   Annual Review of Psychology

Fiji: an open-source platform for biological-image analysis

(2012) Johannes Schindelin et al.   NATURE METHODS

Endocannabinoid Signaling and Synaptic Function

(2012) Pablo E. Castillo et al.   NEURON

Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities

(2012) R. G. Pertwee   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects

(2011) Gai Ling Li et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A novel mouse model of Niemann–Pick type C disease carrying a D1005G-Npc1 mutation comparable to commonly observed human mutations

(2011) Robert A. Maue et al.   HUMAN MOLECULAR GENETICS

Mechanistic and Pharmacological Characterization of PF-04457845: A Highly Potent and Selective Fatty Acid Amide Hydrolase Inhibitor That Reduces Inflammatory and Noninflammatory Pain

(2011) K. Ahn et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease

(2010) Cristina Blázquez et al.   BRAIN

Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum

(2010) David M. Lovinger   NEUROPHARMACOLOGY

Abnormal mGlu 5 Receptor/Endocannabinoid Coupling in Mice Lacking FMRP and BC1 RNA

(2010) Mauro Maccarrone et al.   NEUROPSYCHOPHARMACOLOGY

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2

(2010) R. G. Pertwee et al.   PHARMACOLOGICAL REVIEWS

Improvement in Lipid and Protein Trafficking in Niemann-Pick C1 Cells by Correction of a Secondary Enzyme Defect

(2010) Cecilia Devlin et al.   TRAFFIC

Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders

(2009) Kay Ahn et al.   Expert Opinion on Drug Discovery

Subcellular Origin of Sphingosine 1-Phosphate Is Essential for Its Toxic Effect in Lyase-deficient Neurons

(2009) Nadine Hagen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Caffeine and an adenosine A2Areceptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life

(2009) Giana P. Cognato et al.   JOURNAL OF NEUROCHEMISTRY

ALTERED ANANDAMIDE DEGRADATION IN ATTENTION-DEFICIT/HYPERACTIVITY DISORDER

(2009) D. Centonze et al.   NEUROLOGY

The endocannabinoid system: Its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation

(2009) Vincenzo Di Marzo   PHARMACOLOGICAL RESEARCH

Synaptic Vesicle Docking: Sphingosine Regulates Syntaxin1 Interaction with Munc18

(2009) Paola G. Camoletto et al.   PLoS One

Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis

(2008) Volker Teichgräber et al.   NATURE MEDICINE

Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium

(2008) Emyr Lloyd-Evans et al.   NATURE MEDICINE

Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum

(2008) Mauro Maccarrone et al.   NATURE NEUROSCIENCE

Targeting the endocannabinoid system: to enhance or reduce?

(2008) Vincenzo Di Marzo   NATURE REVIEWS DRUG DISCOVERY

Compartmentalization of endocannabinoids into lipid rafts in a dorsal root ganglion cell line

(2007) N Rimmerman et al.   BRITISH JOURNAL OF PHARMACOLOGY

Good news for CB1receptors: endogenous agonists are in the right place

(2007) M Maccarrone   BRITISH JOURNAL OF PHARMACOLOGY

Anomalous Surface Distribution of Glycosyl Phosphatidyl Inositol–anchored Proteins in Neurons Lacking Acid Sphingomyelinase

(2007) Cristian Galvan et al.   MOLECULAR BIOLOGY OF THE CELL